On December 16, 2015, the Food and Drug Administration (FDA) in the United States approved sugammadex (Bridion, Merck and Co), a modified gamma-cyclodextrin, to be used as a reversal agent. It is a first and unique selective nondepolarizing steroidal muscle relaxant (NDSMR) binding agent with a great affinity for rocuronium and vecuronium. However, there have been several recently published case reports of bradycardia and asystole immediately after sugammadex administration for the reversal. This report presents a case of sugammadex administration followed by rapidly progressing bradycardia leading to asystole and subsequent death. The family has provided the written consent to share this case report.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303763PMC
http://dx.doi.org/10.1155/2020/8767195DOI Listing

Publication Analysis

Top Keywords

bradycardia asystole
8
sugammadex administration
8
sugammadex-associated hypotension
4
hypotension bradycardia
4
asystole death
4
death december
4
december 2015
4
2015 food
4
food drug
4
drug administration
4

Similar Publications

Background: Long QT Syndrome Type-2 (LQT2) is due to loss-of-function variants. encodes K 11.1 that forms a delayed-rectifier potassium channel in the brain and heart.

View Article and Find Full Text PDF

Introduction/objective: Atrial fibrillation (AF) could present with slow ventricular-response; bradycardia could facilitate the emergence of AF. The conviction that one "does not succumb" from bradycardia as an escape rhythm will emerge unless one sustains a fatal injury following syncope is in stark difference with ventricular tachyarrhythmia (VA), which may promptly cause cardiac arrest. However, this is not always the case, as a life-threatening situation may emerge during the bradycardic episode, i.

View Article and Find Full Text PDF

Objective: To investigate the incidence and survival rates of paediatric patients receiving resuscitation for in-hospital cardiac arrest (IHCA) in a teaching hospital in Northern Jordan, comparing initial pulseless rhythms and bradycardia rhythm with poor perfusion.

Design: Retrospective observational study SETTING: An university-affiliated tertiary hospital in Northern Jordan, covering January 2015 to December 2022.

Patients: All hospitalised paediatric patients aged 1 month-18 years who received cardiopulmonary resuscitation (CPR) for cardiac arrest were included in the study.

View Article and Find Full Text PDF

We describe a case of profound bradyarrhythmia after sugammadex administration during ambulatory anesthesia. The patient was a 21-year-old man with autism spectrum disorder undergoing planned general anesthesia for dental treatment. After treatment completion, sugammadex was administered upon awakening, and sudden bradyarrhythmia appeared immediately.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the vagal response (VR) during pulmonary vein isolation (PVI) for atrial fibrillation (AF), focusing on the incidence, risk factors, and outcomes of VR when initiated from the right superior pulmonary vein (RSPV).
  • A total of 702 AF patients were included, with 77 (11.0%) experiencing 81 episodes of VR, primarily in those with paroxysmal AF, and common VR symptoms included sinus arrest and bradycardia.
  • Increased body mass index (BMI) and left ventricular ejection fraction (LVEF) were identified as independent risk factors for VR, but the presence of VR did not correlate with improved long-term outcomes in AF recurrence.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!